What is a Generic Drug?
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Mounjaro (Tirzepatide)
Prescription Required
We don't have this generic product yet!
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
-
Product Details
Description
Mounjaro (tirzepatide) is an injectable medication that's used with diet and exercise to treat type 2 diabetes in adults.
The use of Mounjaro has not been studied in patients who have had pancreatitis.
Mounjaro should not be used in patients with type 1 diabetes.
Fact Table
Formula
C225H348N48O68
License
US FDA
Bioavailability
80%
Legal status
Rx-Only
Chemical Name
Tirzepatide
Elimination half-life
Five days
Dosage (Strength)
2.5mg/-15mg/0.5mL
Pregnancy
Insufficient data
Brands
Mounjaro
Protein binding
99%
PubChem CID
156588324
MedlinePlus
a622044
ChEBI
194186
ATC code
A10BX16
DrugBank
DB15171
KEGG
D11360
Routes of administration
Subcutaneous
Directions
Mounjaro is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose injectable pens.
Follow the instructions that come with your Mounjaro prescription. Talk to your doctor or pharmacist about your questions or concerns.
Use Mounjaro as instructed by your doctor.
Mounjaro should be injected subcutaneously in the abdomen, thigh, or upper arm. Injection sites should be rotated with each dose.
Mounjaro dosage:
The recommended starting dose is to inject 2.5 mg subcutaneously once a week with or without food and increased to 5 mg subcutaneously once a week after 4 weeks of treatment. The dosage may be increased by 2.5 mg increments at 4-week intervals depending on medication response. The dose should not exceed 15 mg subcutaneously once a week.
Ingredients
Mounjaro contains tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist.
Contraindications
Do not use Mounjaro if you or your family has a history of a type of thyroid cancer known as medullary thyroid carcinoma or if you have Multiple Endocrine Neoplasia syndrome type 2.
Do not use Mounjaro if you are allergic to tirzepatide or any of the other ingredients or excipients contained in Mounjaro.
Cautions
WARNING: RISK OF THYROID C-CELL TUMORS
-
In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
- MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO.
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
-
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
-
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
- Discuss your medications, allergies, medical problems, and pregnancy or breastfeeding status with your doctor before you begin treatment with Mounjaro.
- Mounjaro may cause pancreatitis.
- Mounjaro may cause low blood sugar if used with insulin or another type of medication that can lower blood sugar. Test your blood sugar levels and treat low blood sugar as your doctor has instructed.
- Mounjaro may cause allergic reactions that can be severe. Get emergency care right away if you develop shortness of breath, swelling of your face, lips, tongue, or throat, rash, or rapid heart rate.
- Mounjaro can cause acute kidney damage.
- Mounjaro can cause gastrointestinal events that can be severe.
- Mounjaro can cause acute gallbladder disease.
- Patients who have had diabetic retinopathy should be monitored for complications or worsening of diabetic retinopathy.
Side Effects
The most common side effects experienced with Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.
Call your doctor right away if you have side effects that bother you or won't go away.
Reference:
Mounjaro- tirzepatide injection, solution. Eli Lilly and Company; 2022.
Frequently Asked Questions about Mounjaro (Tirzepatide)
What is Mounjaro (Tirzepatide)?
Mounjaro (tirzepatide) injection is used for type 2 diabetes in adults to lower blood sugar levels (blood glucose) and A1C levels. It’s a once-weekly injection that should be used with diet and exercise.
Why is Mounjaro better than Ozempic?
Mounjaro and Ozempic are FDA-approved weekly injections for Type 2 diabetes. Mounjaro, though pricier, is more effective than Ozempic in managing blood sugar levels and promoting weight loss, albeit with potential extra side effects.
How does Mounjaro work?
Mounjaro, administered weekly via injection, mimics GLP-1 and GIP hormones to lower blood sugar.
Why does Mounjaro cause weight loss?
Mounjaro aids weight loss by reducing food intake and slowing gastric emptying, the speed at which food moves through your digestive system.
Do you have to take Mounjaro forever?
Mounjaro is typically used for long-term management of type 2 diabetes. Consult your healthcare provider for personalized guidance on duration.
How long does Mounjaro side effects last?
The duration of side effects can vary. They can last a few days or a few weeks. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.
How much weight do you lose on Mounjaro?
In clinical trials, patients lost varying percentages of weight depending on the dose: 15% for the 5mg dose, 19.5% for the 10mg dose, and 20.9% for the 15mg dose.
Is Mounjaro a controlled substance?
Mounjaro, a 5 mg/0.5 mL pre-filled single-dose pen, is utilized to treat obesity, type 2 diabetes, and falls under the drug class of incretin mimetics. It is not classified as a controlled substance according to the Controlled Substances Act (CSA).
What are the cons of taking Mounjaro?
The cons of taking Mounjaro may include potential side effects such as nausea, diarrhea, decreased appetite, and abdominal pain.
IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.Product Code : 13692
-
-
Product Reviews
